拉贝洛尔联合硫酸镁治疗妊娠期高血压疾病的临床疗效及安全性分析

Clinical efficacy and safety analysis of Labetalol combined with magnesium sulfate in the treatment of hypertensive diseases during pregnancy

目的探究妊娠期高血压疾病患者采取拉贝洛尔联合硫酸镁治疗的临床疗效及安全性。方法选取1200例妊娠期高血压疾病患者,按照入院先后顺序分为对照组与研究组,各600例。对照组采用硫酸镁进行治疗,研究组在对照组基础上联合拉贝洛尔进行治疗。比较两组患者临床疗效、不良反应发生情况及治疗前后血压水平。结果研究组患者总有效率为89.33%,高于对照组的79.50%,差异有统计学意义(P<0.05)。研究组患者不良反应发生率为1.00%,低于对照组的3.33%,差异有统计学意义(P<0.05)。治疗前,两组患者收缩压、舒张压水平比较,差异无统计学意义(P>0.05);治疗后,两组患者收缩压、舒张压水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。结论拉贝洛尔联合硫酸镁治疗妊娠期高血压疾病患者疗效显著,可维持患者血压水平稳定,安全性高,值得临床推广与应用。

Objective To explore the clinical efficacy and safety of labetalol combined with magnesium sulfate in the treatment of hypertensive diseases in pregnancy.Methods 1200 patients with hypertension during pregnancy were selected and divided into control group and study group,600 patients in each group.The control group was treated with magnesium sulfate,and the study group was treated with labetalol on the basis of the control group.The clinical eficacy,adverse reactions and blood pressure before and after treatment were compared between the two groups.Results The total effective rate of the study group was 89.33%,higher than that of the control group 79.50%,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 1.00%,lower than that in the control group(3.33%),and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in systolic and diastolic blood pressure between 2 groups(P>0.05).After treatment,the levels of systolic and diastolic blood pressure in 2 groups were lower than before treatment,and the study group was better than the control group,the difference was statistically significant(P<0.05).Conclusion Labetalol combined with magnesium sulfate in the treatment of hypertensive diseases in pregnancy is effective,can maintain the stable blood pressure level of patients,high safety,worthy of clinical promotion and application.